SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Hera Women's Health is highlighting results from the PRIME multicenter randomized controlled trial sponsored by Sera Prognostics, Inc., with Brian K. Iriye, MD (Hera Women's Health) serving as the ...

Patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly allocated (2:1) to 6 weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 postoperatively (NAC group) or 24 weeks ...

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...

US Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly claimed in public statements that most vaccines recommended for children in the US have not been tested against placebos, ...

Corvus Pharmaceuticals (CRVS) confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled Phase ...